Luseogliflozin (hydrate)
|
|
Luseogliflozin (hydrate) 속성
안전
Luseogliflozin (hydrate) C화학적 특성, 용도, 생산
개요
Luseogliflozin hydrate, which is an SGLT2 inhibitor approved in Japan in March 2014 for the treatment of type 2 diabetes, was discovered by Taisho Pharmaceutical and jointly developed and marketed with Novartis as Lusefi®. Luseogliflozin selectively binds and inhibits human SGLT2 with a Ki of 1.10 nM and IC50 value of 2.26 nM.Luseogliflozin (hydrate) 준비 용품 및 원자재
원자재
준비 용품
Luseogliflozin (hydrate) 공급 업체
글로벌( 4)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Lynnchem | 86-(0)29-85992781 17792393971 |
info@lynnchem.com | China | 4587 | 58 |
| Novachemistry | 44-20819178-90 02081917890 |
info@novachemistry.com | United Kingdom | 4381 | 58 |
| Suzhou Haiben Pharmaceutical Co., Ltd | 14760821013 13564957716 |
1816280386@qq.com | China | 7326 | 58 |
| TargetMol Chemicals Inc. | 15002134094 |
marketing@targetmol.cn | China | 19711 | 58 |